Drug intelligence / Profile preview

HY-Q57215

Development stage: Preclinical
Lead developer: Huazhong University of Science and Technology
Modality: Small Molecules

Overview

HY-Q57215 is a first-in-class small molecule inhibitor targeting the interleukin-35 (IL-35) protein-binding pocket. Identified through a high-throughput virtual screen of 500 million compounds by researchers at Huazhong University of Science and Technology, the compound disrupts the KRAS-induced IL35-STAT3 positive feedback loop. This signaling axis is a critical driver of natural killer (NK) cell exclusion from the tumor microenvironment in KRAS-mutant lung adenocarcinoma (LUAD). By blocking IL-35, HY-Q57215 restores NK cell infiltration and exhibits potent anti-tumor efficacy in preclinical models of LUAD.

Targets

IL12RB2 (Interleukin-12 receptor subunit beta-2)IL27RA (Interleukin-27 receptor subunit alpha)IL-35 (Interleukin-35)STAT3 (Signal Transducer and Activator of Transcription 3)IL6ST (Interleukin-6 receptor subunit beta)

Beyond the preview

Go deeper on HY-Q57215.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY-Q57215.